KR20180100136A - 이중특이적 항체 플랫폼 - Google Patents

이중특이적 항체 플랫폼 Download PDF

Info

Publication number
KR20180100136A
KR20180100136A KR1020187020661A KR20187020661A KR20180100136A KR 20180100136 A KR20180100136 A KR 20180100136A KR 1020187020661 A KR1020187020661 A KR 1020187020661A KR 20187020661 A KR20187020661 A KR 20187020661A KR 20180100136 A KR20180100136 A KR 20180100136A
Authority
KR
South Korea
Prior art keywords
domain
polypeptide
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187020661A
Other languages
English (en)
Korean (ko)
Inventor
마틴 프레이어
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20180100136A publication Critical patent/KR20180100136A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187020661A 2015-12-18 2016-12-15 이중특이적 항체 플랫폼 Abandoned KR20180100136A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18
US62/269,664 2015-12-18
PCT/US2016/066865 WO2017106462A1 (en) 2015-12-18 2016-12-15 Bispecific antibody platform

Publications (1)

Publication Number Publication Date
KR20180100136A true KR20180100136A (ko) 2018-09-07

Family

ID=57681809

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020661A Abandoned KR20180100136A (ko) 2015-12-18 2016-12-15 이중특이적 항체 플랫폼

Country Status (9)

Country Link
US (1) US11447575B2 (enExample)
EP (1) EP3389710A1 (enExample)
JP (2) JP7138046B2 (enExample)
KR (1) KR20180100136A (enExample)
CN (1) CN108601830B (enExample)
AU (1) AU2016370821A1 (enExample)
CA (1) CA3008840A1 (enExample)
MA (1) MA44054A (enExample)
WO (1) WO2017106462A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017315146A1 (en) * 2016-08-26 2019-04-11 Sanofi Multispecific antibodies facilitating selective light chain pairing
WO2019028125A1 (en) 2017-08-01 2019-02-07 Ab Studio Inc. Bispecific antibodies and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
CA3117409A1 (en) 2018-10-29 2020-05-07 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
CN113692416B (zh) * 2019-03-25 2024-11-08 施慧达药业集团(吉林)有限公司 蛋白质异二聚体及其用途
BR112022002012A2 (pt) * 2019-08-15 2022-06-07 Regeneron Pharma Moléculas multispecíficas de ligação a antígeno para células-alvo e usos das mesma
MX2022002239A (es) * 2019-08-23 2022-03-22 Igm Biosciences Inc Glicovariantes de igm.
KR20220071210A (ko) * 2019-09-25 2022-05-31 우니베르지테트 스튜트가르트 변형된 ehd2 도메인을 포함하는 결합 모듈
WO2021139758A1 (zh) * 2020-01-09 2021-07-15 江苏恒瑞医药股份有限公司 新型多肽复合物
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
IL301926A (en) * 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
JP2024517907A (ja) * 2021-05-14 2024-04-23 江蘇恒瑞医薬股▲ふん▼有限公司 抗原結合分子
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ, インコーポレイテッド 免疫エフェクター機能を有する操作されたvlrb抗体
WO2024073482A1 (en) * 2022-09-28 2024-04-04 Dren Bio, Inc. Multispecific antibodies and methods of use thereof
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2824824A1 (en) * 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
RU2014149681A (ru) * 2012-05-24 2016-07-20 Ф. Хоффманн-Ля Рош Аг Антитела с множественной специфичностью
AU2014337135B2 (en) * 2013-10-18 2019-09-19 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
US10982008B2 (en) * 2014-12-05 2021-04-20 Merck Patent Gmbh Domain-exchanged antibody
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
AU2017315146A1 (en) * 2016-08-26 2019-04-11 Sanofi Multispecific antibodies facilitating selective light chain pairing
WO2020131697A2 (en) * 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager

Also Published As

Publication number Publication date
MA44054A (fr) 2018-10-24
CN108601830B (zh) 2023-02-03
JP2019502694A (ja) 2019-01-31
CA3008840A1 (en) 2017-06-22
JP7138046B2 (ja) 2022-09-15
WO2017106462A1 (en) 2017-06-22
AU2016370821A1 (en) 2018-07-12
US20190048098A1 (en) 2019-02-14
JP2021121642A (ja) 2021-08-26
US11447575B2 (en) 2022-09-20
EP3389710A1 (en) 2018-10-24
CN108601830A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
US11447575B2 (en) Bispecific antibody platform
KR102784293B1 (ko) Cd3 결합 폴리펩타이드
JP7286267B2 (ja) 修飾t細胞に対する条件的活性型キメラ抗原受容体
JP2023103451A (ja) 改善された二重特異性ポリペプチド分子
JP2022081654A (ja) 低粘度の抗原結合タンパク質およびそれらの作製方法
JP2021137013A5 (enExample)
KR102609667B1 (ko) 비통합성 바이러스 전달 시스템 및 이와 관련된 방법
CN111995674A (zh) 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用
CN101291692A (zh) 抗addl单克隆抗体及其应用
CA3032512C (en) IMPROVED PROCESSES FOR PRODUCING POLYNUCLEOTIDE LIBRARIES IN VACCINE VIRUS/EUKARYOTIC CELLS
KR20140114833A (ko) 신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드
JP7008406B2 (ja) ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法
CN101633933A (zh) 表达抗体或抗体类似物的重组克鲁维酵母菌及其构建方法与应用
JP2013509188A (ja) Sorf構築物および複数の遺伝子発現
KR20240052854A (ko) Mhc 단백질 기반 이종 이량체를 포함하는 이중 특이적 항체
EP3443011A1 (en) Humanized anti-rage antibody
RU2787060C1 (ru) НУКЛЕОТИДНАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ, КОДИРУЮЩАЯ СЛИТЫЙ БЕЛОК, СОСТОЯЩИЙ ИЗ РАСТВОРИМОГО ВНЕКЛЕТОЧНОГО ФРАГМЕНТА ЧЕЛОВЕЧЕСКОГО Dll4 И КОНСТАНТНОЙ ЧАСТИ ТЯЖЕЛОЙ ЦЕПИ ЧЕЛОВЕЧЕСКОГО IgG4
KR101718764B1 (ko) 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법
US20220281957A1 (en) Modified human variable domains
WO2024182781A1 (en) Coronavirus compositions and uses thereof
CN117177998A (zh) 用于靶向调节性t细胞以增强免疫监视的材料和方法
HK40012343A (en) Low-viscosity antigen binding proteins and methods of making them
EA042409B1 (ru) Полипептиды, связывающие cd3
HK1232562A1 (en) Expression constructs and methods for selecting host cells expressing polypeptides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211209

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration